Back to top
more

BioRad Laboratories (BIO)

(Delayed Data from NYSE)

$275.60 USD

275.60
164,776

-2.61 (-0.94%)

Updated Apr 25, 2024 04:00 PM ET

After-Market: $275.67 +0.07 (0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth C Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (150 out of 251)

Industry: Medical - Products

Better trading starts here.

Zacks News

Headquartered in Hercules, CA, Bio-Rad Laboratories is a manufacturer and global supplier of clinical diagnostics and life science research products in the healthcare, analytical chemistry life science research and other markets. It offers a wide portfolio of products and systems which allow the separation of complex chemical and biological materials and discovery, analysis and purification of their components. Bio-Rad has extensive and direct distribution channels in over 35 countries outside the United States through subsidiaries which focus on sales, customer service and product distribution.

New Strong Sell Stocks for August 9th

BWA, ARR and BIO have been added to the Zacks Rank #5 (Strong Sell) List on August 9, 2023.

Bio-Rad (BIO) Beats on Q2 Earnings Estimates, Cuts 2023 View

Growth across the Life Science portfolio and strong double-digit growth for ddPCR drive Bio-Rad (BIO) Q2 performance.

Bio-Rad Laboratories (BIO) Tops Q2 Earnings Estimates

Bio-Rad (BIO) delivered earnings and revenue surprises of 17.65% and 0.98%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

SurModics (SRDX) Surpasses Q3 Earnings and Revenue Estimates

SurModics (SRDX) delivered earnings and revenue surprises of 213.04% and 96.57%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Bio-Rad Laboratories (BIO) to Post Q2 Earnings: What Awaits?

Bio-Rad Laboratories' (BIO) second-quarter 2023 results are likely to reflect an impressive performance across its Clinical Diagnostics business.

Are Options Traders Betting on a Big Move in Bio-Rad Laboratories (BIO) Stock?

Investors need to pay close attention to Bio-Rad Laboratories (BIO) stock based on the movements in the options market lately.

Bio-Rad Laboratories (BIO) Gains As Market Dips: What You Should Know

In the latest trading session, Bio-Rad Laboratories (BIO) closed at $377.68, marking a +0.09% move from the previous day.

Bio-Rad Laboratories (BIO) Dips More Than Broader Markets: What You Should Know

Bio-Rad Laboratories (BIO) closed at $364.38 in the latest trading session, marking a -0.37% move from the prior day.

Bio-Rad Laboratories (BIO) Stock Sinks As Market Gains: What You Should Know

Bio-Rad Laboratories (BIO) closed at $364.78 in the latest trading session, marking a -0.46% move from the prior day.

Bio-Rad Laboratories (BIO) Dips More Than Broader Markets: What You Should Know

Bio-Rad Laboratories (BIO) closed the most recent trading day at $376.56, moving -0.66% from the previous trading session.

Bio-Rad Laboratories (BIO) Outpaces Stock Market Gains: What You Should Know

In the latest trading session, Bio-Rad Laboratories (BIO) closed at $361.03, marking a +0.43% move from the previous day.

Perrigo (PRGO) Down 7.5% Since Last Earnings Report: Can It Rebound?

Perrigo (PRGO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Bio-Rad Laboratories (BIO) Gains But Lags Market: What You Should Know

In the latest trading session, Bio-Rad Laboratories (BIO) closed at $372.36, marking a +0.27% move from the previous day.

Bio-Rad (BIO) Faces Macroeconomic Headwinds, Rising Expenses

Bio-Rad's (BIO) process chromatography business witnesses a slowdown in the quarter due to tough comparisons and some softness in the bioprocessing market.

Bio-Rad (BIO) Q1 Earnings Beat Estimates, Operating Margin Down

Bio-Rad's (BIO) first-quarter results reflect core strength across the Life Science and Clinical Diagnostics segments amid ongoing supply-chain constraints.

Bio-Rad Laboratories (BIO) Q1 Earnings and Revenues Beat Estimates

Bio-Rad (BIO) delivered earnings and revenue surprises of 3.09% and 0.40%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Can Cigna's (CI) Q1 Earnings Beat on Medical Customers Growth?

The first-quarter results of Cigna (CI) are likely to reflect an expanding customer base and growth in specialty pharmacy services.

Here's Why You Should Retain Exact Sciences (EXAS) Stock Now

Investors are optimistic about Exact Sciences (EXAS) on continued strength across the Screening and Precision Oncology businesses.

Embecta (EMBC) to Report Q2 Earnings: What's in Store?

Embecta's (EMBC) diabetes care business is expected to have progressed in the fiscal second quarter banking on strong execution of its three strategic pillars.

Charles River (CRL) to Report Q1 Earnings: What's in Store?

Continued global demand for research models and associated services are likely to have driven Charles River's (CRL) Q1 revenues.

Are Medical Stocks Lagging BioRad Laboratories (BIO) This Year?

Here is how Bio-Rad Laboratories (BIO) and GSK (GSK) have performed compared to their sector so far this year.

Alcon (ALC) to Report Q1 Earnings: What's in the Cards?

Amid persistent supply-chain headwinds, Alcon's (ALC) first-quarter top-line results are likely to reflect the commercial execution of new product launches across its segments and contributions from strategic alliances.

What's in Store for DENTSPLY SIRONA (XRAY) in Q1 Earnings?

DENTSPLY SIRONA's (XRAY) first-quarter 2023 results are likely to reflect strong performance in the Technologies & Equipment business.

John Blank headshot

What to do with the Real Estate sector?

Shorts have been pounding away. Where to from here?

Quest Diagnostics (DGX) Q1 Earnings Top Estimates, Margins Down

Quest Diagnostics (DGX) base business registers growth in the first quarter of 2023.